Evaluating the Impact of Human Factors and Pen Needle Design on Insulin Pen Injection
Overview
Affiliations
Background: Limited published data exists quantifying the influence of human factors (HF) and pen needle (PN) design on delivery outcomes of pen injection systems. This preclinical in vivo study examines the impact of PN hub design and applied force against the skin during injection on needle penetration depth (NPD).
Method: To precisely locate injection depth, PN injections (20 µl; 2 IU, U-100 volume equivalent) of iodinated contrast agent were administered to the flank of Yorkshire swine across a range of clinically relevant application forces against the skin (0.25, 0.75, 1.25, and 2.0 lbf). The NPD, representing in vivo needle tip depth in SC tissue, from four 32 G × 4 mm PN devices (BD Nano 2nd Gen and three commercial posted-hub PN devices; n = 75/device/force, 1200 total) was measured by fluoroscopic imaging of the resulting depot.
Results: The reengineered hub design more closely achieved the 4 mm target NPD with significantly less variability ( P = .006) than commercial posted-hub PN devices across the range of applied injection forces. Calculations of IM (intramuscular) injection risk completed through in silico probability model, using NPD and average human tissue thickness measurements, displayed a commensurate reduction (~2-8x) compared to conventional PN hub designs.
Conclusions: Quantifiable differences in injection depth were observed between identical labeled length PN devices indicating that hub design features, coupled with aspects of variable injection technique, may influence injection depth accuracy and consistency. The reengineered hub design may reduce the impact of unintended individual technique differences by improving target injection depth consistency and reducing IM injection potential.
Staples A, Poulsen M, Praestmark K, Sparre T, Traberg M J Diabetes Sci Technol. 2024; :19322968241231996.
PMID: 38388411 PMC: 11571378. DOI: 10.1177/19322968241231996.
Optimising Insulin Injection Techniques to Improve Diabetes Outcomes.
Kalra S, Pathan F, Kshanti I, Bay N, Nagase T, Oliveria T Diabetes Ther. 2023; 14(11):1785-1799.
PMID: 37715887 PMC: 10570228. DOI: 10.1007/s13300-023-01460-y.
Imaging of large volume subcutaneous deposition using MRI: exploratory clinical study results.
Pettis R, Woodley W, Ossege K, Blum A, Bolick N, Rini C Drug Deliv Transl Res. 2023; 13(9):2353-2366.
PMID: 36913105 PMC: 10382358. DOI: 10.1007/s13346-023-01318-7.
Diabetes Technology Meeting 2021.
Xu N, Nguyen K, DuBord A, Pickup J, Sherr J, Teymourian H J Diabetes Sci Technol. 2022; 16(4):1016-1056.
PMID: 35499170 PMC: 9264449. DOI: 10.1177/19322968221090279.
Population Pharmacokinetics of Cotadutide in Subjects with Type 2 Diabetes.
Guan Y, Ly N, Li J, Arends R Clin Pharmacokinet. 2022; 61(6):833-845.
PMID: 35235191 DOI: 10.1007/s40262-021-01094-y.